Edwards Lifesciences Corporation (EW)
Last Price$71.4(0.3%)
Market Cap$43.4B
EW Rating
EW Quality rating performance
EW Intrinsic Value
Key Highlights:
As of Mar 03, 2025 EW Relative Value is $66.1, which is overvalued by 7.5%, compared to current share price of $71.4.
As of Mar 03, 2025 EW DCF Value is $43.6, which is overvalued by 38.9%, compared to current share price of $71.4.
EW Share Price History
1W (1.9%)
1M 0.0%
6M 3.8%
YTD (5.5%)
1Y (18.0%)
3Y (36.2%)
5Y 2.7%
10Y 218.3%
Share Price
Intrinsic Value
Drawdown
Total Return
vs SP500
vs NASDAQ
Crunching data... Almost there!
EW Stock Metrics
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Base
$43.4B
$39.7B
$5,872.6M
$502.2M
Shares Outstanding
608M
Employees
16K
Growth (CAGR)
7.2%
14.0%
41.12%
(9.0%)
(64.98%)
Profitability
77.8%
27.2%
70.8%
13.7%
8.6%
12.1%
Intrinsic Value
$54.1 (24.2% overvalued)
$43.3
$64.9
($255.1)
($345.1)
42.0%
Return on Capital
Financial Health
$4,446.1M
($3,739.4M)
(7.4x)
57.4x
Dividends
Earnings
Apr 23, 2025
MISS by (14.0%)
BEAT by 0.7%
21.8%
6 Beat & 4 Miss
EW Stock Financials
EW Income Statement Metrics
Annual
Quarterly
LTM
EW Cash Flow Statement Metrics
Annual
Quarterly
LTM
Operating Cash Flow (OCF)
$542.3M N/A YoY
Capital Expenditure (CAPEX)
($252.4M) N/A YoY
Free Cash Flow (FCF)
$289.9M N/A YoY
EW Income Statement Overview
Crunching data... Almost there!
EW Balance Sheet Overview
Annual
Quarterly
LTM
Dec'15
Dec'16
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Dec'24
Assets
Liabilities
Total assets
$13.1B
Current assets ($6,285.4M, 48.1% of total)
$3,045.2M (23.3%)
$727.4M (5.6%)
Other current assets
$2,512.8M (19.2%)
Non-current assets ($6,769.9M, 51.9% of total)
$307.9M (2.4%)
$1,784.2M (13.7%)
$1,176.6M (9.0%)
Other non-current assets
$3,501.2M (26.8%)
Financial position
($2,942.9M)
Cash & Short-term
Investments
Total Debt
EW Stock Ratios
Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
EW Earnings Surprises
Crunching data... Almost there!
EW Dividends
EW Dividend Yield
Crunching data... Almost there!
EW Dividend Per Share
3Y
10Y
30Y
Annual
Quarterly
LTM
Competing with EW
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$43.4B | 6.1 | $54.1 24.2% overvalued | (18.0%) | $5,872.6M | $502.2M | 0.9% | 8.6% | 77.8% | 25.8% | 7.4% | |
$242.4B | 7.0 | $174.5 24.5% undervalued | 19.2% | $42.0B | $6,351.0M | 4.6% | 15.1% | 55.6% | 25.3% | 31.4% | |
$154.5B | 6.7 | $34.2 67.4% overvalued | 55.5% | $16.7B | $2,438.0M | 17.6% | 14.6% | 67.0% | 8.0% | 50.7% | |
$150.5B | 6.6 | $305.1 22.7% overvalued | 12.0% | $22.6B | $3,487.0M | 10.2% | 15.4% | 62.8% | 14.6% | 28.4% | |
$120.9B | 6.2 | $114.6 21.5% undervalued | 14.7% | $33.2B | $5,467.0M | 2.7% | 16.5% | 52.7% | 7.4% | 53.6% | |
$34.9B | 7.0 | $43.1 49.8% overvalued | (29.7%) | $4,033.0M | $453.9M | 11.3% | 11.3% | 60.4% | 21.7% | 120.3% | |
$24.7B | 5.3 | $65.0 146.8% undervalued | 34.0% | €18.0B | €274.0M | (0.8%) | 1.5% | 43.1% | (4.2%) | 63.4% | |
$21.9B | 6.2 | $199.6 10.4% overvalued | (3.8%) | $5,398.4M | $751.4M | (0.2%) | 13.9% | 44.7% | 8.2% | 1.9% | |
$21.6B | 5.9 | $181.2 72.0% undervalued | (15.3%) | $5,655.4M | $1,132.4M | (23.5%) | 20.0% | 64.3% | 4.5% | 43.0% | |
$19.4B | 7.9 | $134.5 50.7% overvalued | 62.5% | $1,900.3M | $303.0M | 12.0% | 15.9% | 76.4% | 29.7% | 6.9% | |
$13.6B | 6.0 | $190.0 8.5% undervalued | (43.2%) | $3,999.0M | $622.7M | 3.5% | 15.6% | 70.3% | 14.2% | 2.3% |
FAQ
What is Edwards Lifesciences Corporation (EW) stock rating?
As of today, Edwards Lifesciences Corporation has a stock rating of 6 (out of 10), which is considered Good.
is Edwards Lifesciences Corporation (EW) a good stock to buy?
As of today, Edwards Lifesciences Corporation has a Good stock rating, which is 24.2% overvalued. According to Value Sense backtesting, stocks with similar profile tend to underperform the market by 4.6%.